Brockmöller J - Search Results

1

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolić I, Koepsell H, Brockmöller J. Tzvetkov MV, et al. Among authors: brockmoller j. Clin Pharmacol Ther. 2009 Sep;86(3):299-306. doi: 10.1038/clpt.2009.92. Epub 2009 Jun 17. Clin Pharmacol Ther. 2009. PMID: 19536068

2

Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers.

Rost KL, Brockmöller J, Weber W, Roots I. Rost KL, et al. Among authors: brockmoller j. Clin Pharmacol Ther. 1991 Aug;50(2):141-9. doi: 10.1038/clpt.1991.118. Clin Pharmacol Ther. 1991. PMID: 1868675 Clinical Trial.

3

Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population.

Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I. Mrozikiewicz PM, et al. Among authors: brockmoller j. Clin Pharmacol Ther. 1996 Apr;59(4):376-82. doi: 10.1016/S0009-9236(96)90104-6. Clin Pharmacol Ther. 1996. PMID: 8612380

4

Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum).

Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Johne A, et al. Among authors: brockmoller j. Clin Pharmacol Ther. 1999 Oct;66(4):338-45. doi: 10.1053/cp.1999.v66.a101944. Clin Pharmacol Ther. 1999. PMID: 10546917 Clinical Trial.

5

Omeprazole weakly inhibits CYP1A2 activity in man.

Rost KL, Fuhr U, Thomsen T, Zaigler M, Brockmöller J, Bohnemeier H, Roots I. Rost KL, et al. Among authors: brockmoller j. Int J Clin Pharmacol Ther. 1999 Nov;37(11):567-74. Int J Clin Pharmacol Ther. 1999. PMID: 10584979 Clinical Trial.

6

Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin.

Mai I, Krüger H, Budde K, Johne A, Brockmöller J, Neumayer HH, Roots I. Mai I, et al. Among authors: brockmoller j. Int J Clin Pharmacol Ther. 2000 Oct;38(10):500-2. doi: 10.5414/cpp38500. Int J Clin Pharmacol Ther. 2000. PMID: 11073292

7

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C, Roots I, Brockmöller J. Kirchheiner J, et al. Among authors: brockmoller j. Pharmacogenetics. 2002 Mar;12(2):101-9. doi: 10.1097/00008571-200203000-00004. Pharmacogenetics. 2002. PMID: 11875364

8

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.

Kirchheiner J, Brockmöller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I. Kirchheiner J, et al. Among authors: brockmoller j. Clin Pharmacol Ther. 2002 Apr;71(4):286-96. doi: 10.1067/mcp.2002.122476. Clin Pharmacol Ther. 2002. PMID: 11956512

9

Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.

Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmöller J. Kirchheiner J, et al. Among authors: brockmoller j. Clin Pharmacol Ther. 2002 Jul;72(1):62-75. doi: 10.1067/mcp.2002.125726. Clin Pharmacol Ther. 2002. PMID: 12152005 Clinical Trial.

10

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.

Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J. Kirchheiner J, et al. Among authors: brockmoller j. Pharmacogenetics. 2002 Oct;12(7):571-80. doi: 10.1097/00008571-200210000-00010. Pharmacogenetics. 2002. PMID: 12360109

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

306 results

Search Page